Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Articaine, Lidocaine, and Mepivacaine for Irreversible Pulpitis
NCT02054767Phase 4
Key facts
- Status
- Completed
- Start
- Aug 2010
- Primary completion
- Nov 2012
- Countries
- 1
- Sponsor
- Universidade de São Paulo
- Modality
- Small Molecules
- Conditions
- irreversible pulpitis
01
Overview
Phase 4, randomised, double-blind trial of articaine, lidocaine and mepivacaine in irreversible pulpitis, sponsored by Universidade de São Paulo. Primary endpoint: Pulpal anesthesia. Started Aug 2010; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients with a clinical diagnosis of irreversible pulpitis in a mandibular molar, in good health, with at least one adjacent tooth and a healthy canine.
04
Endpoints
Primary
Pulpal anesthesia
Beyond the preview
Go deeper on NCT02054767.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054767.